Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
19 Junio 2020 - 7:00AM
Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube,
Ph.D., chief executive officer, will present at the BMO 2020
Prescriptions for Success Healthcare Conference on Tuesday, June
23, 2020 at 10:00 a.m. ET.
A live webcast of the presentation will be
available at http://ir.retrophin.com/events and an archived replay
will be accessible for up to 30 days.
About Retrophin
Retrophin is a biopharmaceutical company
specializing in identifying, developing and delivering
life-changing therapies to people living with rare disease. The
Company’s approach centers on its pipeline featuring sparsentan, a
product candidate in late-stage development for focal segmental
glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare
disorders characterized by progressive scarring of the kidney often
leading to end-stage renal disease. Research in additional rare
diseases is also underway, including partnerships with leaders in
patient advocacy and government research to identify potential
therapeutics for NGLY1 deficiency and Alagille syndrome, conditions
with no approved treatment options. Retrophin’s R&D efforts are
supported by revenues from the Company’s commercial products
Chenodal®, Cholbam®, Thiola® and Thiola EC®.
Retrophin.com
Contact:Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate
Communications888-969-7879
IR@retrophin.com
Retrophin (NASDAQ:RTRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Retrophin (NASDAQ:RTRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Retrophin Inc (NASDAQ): 0 recent articles
Más de Artículos de Noticias